Your browser is no longer supported. Please, upgrade your browser.
Settings
KOD Kodiak Sciences Inc. daily Stock Chart
KOD [NASD]
Kodiak Sciences Inc.
Index- P/E- EPS (ttm)-1.58 Insider Own0.40% Shs Outstand44.83M Perf Week8.56%
Market Cap2.38B Forward P/E- EPS next Y-4.41 Insider Trans269.72% Shs Float33.63M Perf Month-18.36%
Income-63.80M PEG- EPS next Q-0.65 Inst Own83.20% Short Float14.53% Perf Quarter4.10%
Sales- P/S- EPS this Y-11.40% Inst Trans0.19% Short Ratio15.88 Perf Half Y-21.25%
Book/sh7.31 P/B7.22 EPS next Y-53.10% ROA-26.90% Target Price83.19 Perf Year299.02%
Cash/sh9.36 P/C5.64 EPS next 5Y12.40% ROE-31.80% 52W Range9.47 - 82.75 Perf YTD-26.69%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.25% Beta-
Dividend %- Quick Ratio30.70 Sales past 5Y- Gross Margin- 52W Low457.02% ATR4.01
Employees41 Current Ratio30.70 Sales Q/Q- Oper. Margin- RSI (14)43.56 Volatility5.80% 7.63%
OptionableYes Debt/Eq0.00 EPS Q/Q-153.90% Profit Margin- Rel Volume0.86 Prev Close53.44
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume307.55K Price52.75
Recom2.00 SMA20-7.17% SMA50-9.71% SMA2005.72% Volume265,451 Change-1.29%
Mar-31-20Initiated BMO Capital Markets Outperform $74
Mar-03-20Initiated Goldman Buy $80
Feb-18-20Downgrade Barclays Overweight → Equal Weight $69
Feb-06-20Initiated SunTrust Buy
Jan-08-20Initiated ROTH Capital Buy $115
Jan-03-20Initiated Jefferies Buy $100
Dec-24-19Initiated JP Morgan Overweight $82
Oct-15-19Reiterated Chardan Capital Markets Buy $22.50 → $35
Feb-20-19Initiated Chardan Capital Markets Buy $22.50
Oct-29-18Initiated Morgan Stanley Overweight $20
Oct-29-18Initiated BofA/Merrill Buy $14
Oct-29-18Initiated Barclays Overweight $20
Jul-10-20 04:00PM  
Jul-07-20 08:38AM  
Jul-05-20 03:30PM  
Jun-12-20 10:20PM  
Jun-05-20 12:00PM  
May-29-20 01:38PM  
May-28-20 08:22AM  
May-26-20 11:02AM  
May-13-20 07:01AM  
May-11-20 04:13PM  
05:30AM  
May-08-20 04:30PM  
Apr-07-20 11:35AM  
Apr-02-20 04:08PM  
Mar-24-20 04:23PM  
08:51AM  
Mar-23-20 01:37PM  
Mar-18-20 02:29PM  
Mar-16-20 05:30AM  
Mar-03-20 12:08PM  
Feb-27-20 06:00AM  
Feb-21-20 03:14PM  
Feb-08-20 03:30PM  
Jan-14-20 03:56PM  
Jan-08-20 06:00AM  
Dec-27-19 02:19PM  
Dec-26-19 07:55AM  
Dec-25-19 11:30AM  
Dec-24-19 12:00PM  
Dec-22-19 01:21PM  
Dec-20-19 07:30AM  
Dec-19-19 04:01PM  
12:20PM  
Dec-14-19 07:30AM  
Dec-06-19 04:15PM  
Dec-03-19 09:07PM  
08:41AM  
07:59AM  
Dec-02-19 05:00PM  
09:51AM  
07:00AM  
06:00AM  
Nov-27-19 12:15PM  
Nov-12-19 07:20AM  
05:30AM  
Nov-08-19 07:00AM  
Oct-11-19 07:58PM  
06:00AM  
Oct-10-19 07:39PM  
Oct-07-19 06:00AM  
Oct-04-19 02:27PM  
Sep-15-19 06:08AM  
Sep-12-19 06:00AM  
Sep-06-19 06:00AM  
Sep-04-19 06:30PM  
Aug-23-19 11:36AM  
Aug-14-19 05:30AM  
Aug-08-19 06:00AM  
Jul-27-19 12:47PM  
Jul-24-19 07:00AM  
Jul-17-19 10:09AM  
Jun-17-19 09:56AM  
May-30-19 07:27PM  
May-25-19 10:26AM  
May-24-19 09:46AM  
May-15-19 06:00AM  
May-09-19 07:00AM  
Apr-25-19 04:05PM  
Mar-28-19 06:00AM  
Mar-07-19 06:00AM  
Mar-01-19 10:28AM  
Feb-28-19 08:15AM  
Feb-27-19 11:00AM  
Feb-08-19 07:00AM  
Jan-18-19 10:35AM  
Dec-24-18 08:00AM  
Dec-21-18 06:00AM  
Dec-05-18 10:35AM  
Nov-16-18 06:00AM  
Oct-31-18 03:34PM  
Oct-26-18 03:05PM  
Oct-10-18 07:00AM  
Oct-04-18 11:35AM  
06:42AM  
Oct-03-18 10:59PM  
Sep-30-18 09:41AM  
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EHRLICH JASONSee RemarksJul 02Option Exercise10.292,70027,78333,984Jul 07 07:05 PM
EHRLICH JASONSee RemarksJun 22Option Exercise10.296,95071,51638,234Jun 24 05:09 PM
EHRLICH JASONSee RemarksJun 22Sale60.546,950420,74731,284Jun 24 05:09 PM
EHRLICH JASONSee RemarksMay 20Option Exercise10.296,95071,51638,234May 22 04:41 PM
EHRLICH JASONSee RemarksMay 20Sale60.726,950421,98931,284May 22 04:41 PM
EHRLICH JASONSee RemarksApr 20Option Exercise10.296,95071,51638,234Apr 22 05:01 PM
EHRLICH JASONSee RemarksApr 20Sale54.126,950376,11531,284Apr 22 05:01 PM
EHRLICH JASONSee RemarksApr 09Sale48.562,200106,83031,284Apr 13 06:37 PM
Liang HongSVP, Discovery MedicineApr 02Sale42.344,000169,360130,166Apr 06 08:08 PM
Liang HongSVP, Discovery MedicineMar 26Sale47.784,000191,112134,166Mar 30 04:51 PM
EHRLICH JASONSee RemarksMar 20Option Exercise10.296,95071,51629,492Mar 24 04:45 PM
Levy Richard SDirectorMar 20Buy44.331,00044,3301,000Mar 24 04:50 PM
EHRLICH JASONSee RemarksMar 20Sale45.006,950312,76222,542Mar 24 04:45 PM
Liang HongSVP, Discovery MedicineMar 19Sale39.454,000157,811138,166Mar 23 04:36 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy37.3735,4001,322,97710,602,550Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy38.9910,000389,85010,570,083Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy39.97104,6004,180,97710,560,911Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Buy57.99100,0005,799,44110,464,977Feb 26 05:06 PM
BAKER BROS. ADVISORS LPDirectorFeb 25Buy57.91206,12611,937,24810,373,248Feb 26 05:06 PM
BAKER BROS. ADVISORS LPDirectorFeb 24Buy57.5671,1234,093,55310,184,170Feb 26 05:06 PM
EHRLICH JASONSee RemarksDec 23Option Exercise10.291,07511,06222,542Dec 27 05:53 PM
BAKER BROS. ADVISORS LPDirectorDec 06Buy46.001,902,17387,499,95810,118,929Dec 06 04:46 PM
Liang HongSVP, Discovery MedicineDec 02Option Exercise1.0542,16644,111142,166Dec 04 05:33 PM